Naringenin inhibits glucose uptake in MCF-7 breast cancer cells: a mechanism for impaired cellular proliferation
Regulation of the estrogen receptor α minimal promoter by Sp1, USF-1 and ERα
A family-based genetic association study of variants in estrogen-metabolism genes COMT and CYP1B1 and breast cancer risk
Hormonal factors and breast tumor proliferation: Do factors that affect cancer risk also affect tumor growth?
A Southwest Oncology Group randomized phase II study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis
AstraZeneca Scholars Program
Breast reconstruction: the perforator flap technique
LHRH-analogue therapy with leuprorelin-acetate 3-months depot offers similar efficacy to conventional adjuvant CMF chemotherapy in receptor positive, node positive breast cancer patients
Expression of BP1, a homeobox gene, correlates with breast cancer aggressiveness
Randomized placebo-controlled trial of letrozole in postmenopausal women with early breast cancer completing 5 years of tamoxifen
TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up
ABI-007 (ABRAXANE™), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs taxol in MBC: a phase III trial
Effects of formalin fixation on immunohistochemical expression of phosphorylated proteins in human breast cancer
Low-level HER-2/neu gene amplification by fluorescence in situ hybridization and responsiveness to single agent Herceptin® immunotherapy among women with metastatic breast cancer
Use of biopsy marker in patients undergoing neoadjuvant chemotherapy
The effectiveness of community-based organizations in linking underserved women to breast cancer screening
Preclinical therapy of breast cancer using a humanized, radioiodinated, anti-epithelial glycoprotein-1 antibody: advantage of a residualizing 131I label
Hyperplastic and disorganized mammary gland growth resulting from oxidative stress and the absence of mitochondrial superoxide dismutase
Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4 OHT gel to oral tamoxifen
Differential stabilization of estrogen receptor alpha (ERα) protein by selective estrogen receptor modulators (SERMs)
Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland
Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment
An international, randomized phase III clinical trial of STn-KLH (Theratope®) therapeutic cancer vaccine in metastatic breast cancer patients
First-line trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001)
Increased plasma IGF receptor (IGF-IR) in patients with elevated serum HER-2/neu